Dario Gutierrez

Dario Gutierrez

Company: TCR2 Therapeutics

Job title: VP, Discovery Research & Innovation


Dr. Dario Gutierrez is the Vice President of Discovery Research and Innovation at TCR2 Therapeutics where he heads the Biologics, T-Cell engineering and Innovation Departments. Before joining TCR2, he was the Head of Investigational Biology and Immuno-Biology at the Merck Research Labs Cambridge Exploratory Science Center. Previously, he led the Immune Tolerance group at Evelo Biosciences in Cambridge MA. He received a Bachelor of Science in Chemistry from California State University, San Bernardino, a Ph.D. from the Department of Molecular Physiology and Biophysics in the laboratory of Dr. Alyssa Hasty at Vanderbilt University, and performed a postdoctoral fellowship in the laboratory of Hans-Reimer Rodewald at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. He has authored multiple publications on the role of the immune system in metabolic and autoimmune diseases, and has contributed to multiple drug discovery programs that have advanced into early and late development.



Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuC™) T cells 4:10 pm

• T Cell Receptor Fusion Construct (TRuC™) T cells are engineered to express a fusion protein that comprises an antibody-derived binder tethered to the CD3ε signalling subunit • Upon integration of the TRuC into the TCR, it recognizes tumor surface antigens independent of HLA and uses the complete receptor complex to trigger a comprehensive T…Read more

day: Track A - Day 2 - 1PM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.